Analyst Price Targets — SRTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:54 am | — | Industrial Alliance Securities | $6.50 | $4.11 | TheFly | Sensus Healthcare price target lowered to $6.50 from $7.50 at Alliance Global |
| February 17, 2026 1:57 pm | Anthony Vendetti | Maxim Group | $6.00 | $3.91 | TheFly | Sensus Healthcare price target lowered to $6 from $8 at Maxim |
| May 13, 2024 7:17 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $5.56 | StreetInsider | Sensus Healthcare (SRTS) PT Raised to $10 at H.C. Wainwright |
| May 6, 2022 12:12 pm | — | H.C. Wainwright | $16.00 | $7.71 | Benzinga | HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $16 |
Latest News for SRTS
Sensus Healthcare NASDAQ: SRTS said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced that SkinCure Oncology and Sensus Healthcare have amicably resolved their dispute and are moving forward constructively with a shared commitment to patient care and clinical excellence. In March 2026,…
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended…
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRTS.
U.S. House Trading
No House trades found for SRTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.